Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025)
Keros Therapeutics' (KROS) quarterly Capital Expenditures came in at $1.5 million in Q4 2025, up 434.95% YoY from $289000.0 in Q4 2024, and up 220.78% on a QoQ basis from -$1.3 million in Q3 2025.
Keros Therapeutics (KROS) Capital Expenditures (2019 - 2025) Analysis & Trends
Keros Therapeutics (KROS) has 7 years of Capital Expenditures data on file, last reported at $1.5 million in Q4 2025.
- Quarterly Capital Expenditures rose 434.95% year-over-year to $1.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.6 million (down 19.68% YoY) and the FY2025 annual result came in at $1.6 million, down 19.68% from the prior year.
- Capital Expenditures improved to $1.5 million in Q4 2025, from -$1.3 million in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $1.5 million in Q4 2025 to a low of -$1.3 million in Q3 2025.
- A 5-year average of $352250.0 and a median of $337500.0 in 2024 frame the typical range for Capital Expenditures.
- Annual changes were most pronounced in 2021 — Capital Expenditures tumbled 850.0% — and 2024, when it surged 995.24%.
- Tracing KROS's Capital Expenditures over 5 years: stood at $159000.0 in 2021, then plunged by 61.01% to $62000.0 in 2022, then soared by 772.58% to $541000.0 in 2023, then tumbled by 46.58% to $289000.0 in 2024, then surged by 434.95% to $1.5 million in 2025.
- The last three Capital Expenditures figures came in at $1.5 million (Q4 2025), -$1.3 million (Q3 2025), and $720000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Keros Therapeutics | 217.61 Mn | -40.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.55 Mn |
| Dec 31, 2025 | 1.55 Mn |
| Sep 30, 2025 | -1.28 Mn |
| Sep 30, 2025 | -1.28 Mn |
| Jun 30, 2025 | 720,000.00 |
| Jun 30, 2025 | 720,000.00 |
| Mar 31, 2025 | 565,000.00 |
| Mar 31, 2025 | 565,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Dec 31, 2024 | 289,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Sep 30, 2024 | 386,000.00 |
| Jun 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.03 Mn |
| Mar 31, 2024 | 230,000.00 |
| Mar 31, 2024 | 230,000.00 |
| Dec 31, 2023 | 541,000.00 |
| Dec 31, 2023 | 541,000.00 |
| Sep 30, 2023 | 550,000.00 |
| Sep 30, 2023 | 550,000.00 |